4 unknown. 4 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Unknown 4 |
| Phase 2 | 1 | Unknown 1 |
Follow Eylea: new trials by email Literature Review of Eylea trials Research Report on Eylea
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of RC28-E Versus Aflibercept RC28-E, Aflibercept - Wet Age-related Macular Degeneration | Phase 3 | Unknown | RemeGen Co., Ltd. | 432 | 2023-03-14 | 2023-08-31 |
| A Study to Compare LY09004 and Eylea in the Treatment of Wet Age-related Macular Degeneration（wAMD） LY09004, Eylea - Age Related Macular Degeneration | Phase 3 | Unknown | Luye Pharma Group Ltd. | 416 | 2020-11-01 | 2020-10-01 |
| Treat and Extend Analysis Trial With Aflibercept in Wet-AMD Aflibercept - Wet Age-related Macular Degeneration | Phase 3 | Unknown | Michel Giunta | 40 | 2019-07-24 | 2022-06-14 |
| Comparison of Pharmacokinetics of and Effect on Systemic VEGF Levels in Age Related Macular Degeneration Patients Ranibizumab, Bevacizumab, Aflibercept - Age Related Macular Degeneration | Phase 2 / Phase 3 | Unknown | East Florida Eye Institute | 80 | 2014-12-01 | 2015-08-11 |
East Florida Eye Institute (1) · Luye Pharma Group Ltd. (1) · Michel Giunta (1) · RemeGen Co., Ltd. (1)
Canada (1) · China (1) · United States (1)
Ronald E Frenkel, MD (1) · Youxin Chen (1)